Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Quoin Pharmaceuticals ( (QNRX) ) just unveiled an announcement.
At the 2025 Annual Meeting, Quoin Pharmaceuticals‘ shareholders approved several key proposals, including an increase in authorized share capital and a new compensation policy for executives and directors. Additionally, the company announced the appointment of Sally Lawlor as the new Chief Financial Officer, succeeding Gordon Dunn. Ms. Lawlor brings over 20 years of financial leadership experience, which is expected to support Quoin’s strategic growth as it advances its lead product, QRX003, through pivotal clinical studies and prepares for potential commercialization.
The most recent analyst rating on (QNRX) stock is a Buy with a $70.00 price target. To see the full list of analyst forecasts on Quoin Pharmaceuticals stock, see the QNRX Stock Forecast page.
Spark’s Take on QNRX Stock
According to Spark, TipRanks’ AI Analyst, QNRX is a Underperform.
Quoin Pharmaceuticals is in a challenging financial position with no revenue generation and high reliance on external financing. The technical analysis indicates a bearish trend, though some technical indicators suggest the stock may be oversold. Valuation metrics reflect the company’s lack of profitability. The combination of these factors results in a low stock score, highlighting significant risks to investors.
To see Spark’s full report on QNRX stock, click here.
More about Quoin Pharmaceuticals
Quoin Pharmaceuticals Ltd. is a late clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products for rare and orphan diseases. The company is committed to addressing unmet medical needs with a pipeline that includes products targeting conditions such as Netherton Syndrome, Peeling Skin Syndrome, and other rare dermatologic diseases.
Average Trading Volume: 10,180
Technical Sentiment Signal: Strong Sell
Current Market Cap: $4.15M
For an in-depth examination of QNRX stock, go to TipRanks’ Overview page.